Greene v. Entergy Operations

Court of Appeals for the Fifth Circuit·Decided August 6, 2025·No. 24-60603·Unpublished

Opinion

United States Court of Appeals for the Fifth Circuit

____________ United States Court of Appeals Fifth Circuit

No. 24-60603

FILED August 6, 2025

Lyle W. Cayce

Jairus K. Greene, Clerk

Plaintiff—Appellant,

versus

Entergy Operations, Incorporated,

Defendant—Appellee.

Appeal from the United States District Court for the Southern District of Mississippi USDC No. 5:23-CV-16

Before Wiener, Willett, and Ho, Circuit Judges. Per Curiam: * Jairus Greene challenges his termination from a nuclear power plant operated by Entergy Operations, Inc. The district court granted summary judgment for Entergy. Finding no reversible error, we AFFIRM.

*

This opinion is not designated for publication. See 5th Cir. R. 47.5.

No. 24-60603

I

A

Entergy operates the Grand Gulf nuclear power plant in Port Gibson, Mississippi. As a nuclear reactor licensee, the facility is subject to Nuclear Regulatory Commission (Commission) regulations, including various restrictions on personnel access. The Commission requires such facilities to “implement drug and alcohol testing programs” to “deter and detect substance abuse.” 10 C.F.R. § 26.31(a). To comply, Entergy maintains two internal review frameworks that operate in tandem: unescorted access authorization and a Fitness for Duty (FFD) Program. The Program screens for employees “under the influence of any substance, legal or illegal, or mentally or physically impaired from any cause, which in any way adversely affects their ability to safely and competently perform their duties.” 10 C.F.R. § 26.23(b). Employees receive unescorted access privileges only if they submit to routine drug and alcohol testing.

Following drug testing, the Commission requires a Medical Review Officer to “review and interpret positive, adulterated, substituted, invalid, and dilute test results obtained through the licensee’s or other entity’s testing program and to identify any evidence of subversion of the testing process.” 10 C.F.R. § 26.183(c). These Medical Officers must “examine alternate medical explanations for any positive . . . test result,” which may involve “conducting a medical interview with the donor,” “reviewing the donor’s medical history,” or “review[ing] all medical records that the donor may make available” to show that the result stemmed from the responsible use of prescribed medication. Id. Medical Officers may review only those specimens “collected and processed” in accordance with the Commission’s regulations. Id.

No. 24-60603

The Commission also mandates that “nuclear licensees share certain information about persons who have applied for [unescorted access authorization] after the applicants have signed releases.” See 10 C.F.R. § 73.56(d)(4)(v). Entergy and other nuclear facilities that participate in the Commission’s Personnel Access Data System (PADS) “enter information into . . . a centralized computer database accessible to other licensees across the country.” See NEI 03-01, § 2(b)–(e). This information includes, among other things, the date an employee’s unescorted access authorization is granted, the number of chemical samples collected under the Fitness for Duty Program, and the reasons for those tests. NEI 03-01, § 12.1(c). If a licensee revokes an employee’s access, that revocation must also be recorded in the data system.

B

With this regulatory backdrop, we turn to the facts of the case. Entergy hired Jairus Greene in 2019 as an Assessor on its Nuclear Independent Oversight team. The team was responsible for “identifying and reporting gaps in compliance . . . so Entergy can address them.” As an Assessor, Greene was required to comply with Entergy’s Fitness for Duty Program and to maintain his unescorted access authorization. 1 From September 2019—when he was hired—to May 2021, Greene submitted multiple urine drug tests. The first two tests were negative for marijuana metabolites and other illegal substances. The next seven, however, returned positive results for marijuana metabolites above the 50 ng/mL screening threshold. Still, the Medical Review Officer determined that the test results did not constitute FFD violations because Greene provided

1 Greene signed a consent and release authorizing Entergy to share his unescorted access authorization information on PADS.

No. 24-60603

documentation for an unexpired prescription of Dronabinol (name brand Marinol), which had been prescribed to treat his glaucoma.

Several months later, in May 2021, Entergy contracted with new Medical Officers—Dr. Monfee and Dr. Barron. In September 2021, Greene consented to a follow-up urine drug test, which returned a positive result. The Officers conferred with Greene and learned that his prescription for Marinol—which “could provide a legitimate medical explanation” for the result—had expired two months earlier, in July. Citing the expired prescription and elevated THC levels, Dr. Monfee declined to excuse the result and ordered additional testing for THCV—a compound present in marijuana but not in Marinol. The outsourced lab reported that the sample was “[p]ositive for THCV” and “[could not] be the result of the sole use of Marinol.” Based on this result, Dr. Barron deemed the result an FFD violation, “confirmed that no acceptable medical explanation existed,” and informed Greene of his right to retest the original sample.

On October 14, 2021, Entergy revoked Greene’s unescorted access privileges for two weeks and placed him on unpaid leave. The company also reported this information in PADS. Five days later, Greene requested a retest of the September sample. Dr. Monfee reported that the specimen again tested positive for THCV.

In November, Greene submitted another urine sample. The lab reported a positive result, prompting Dr. Monfee to order follow-up testing for THCV to account for Greene’s Marinol use. Although the sample again tested positive for THCV, Dr. Monfee “did not deem it an FFD violation because the ‘drop in level suggest[ed] no continued use of THC since last test.’” Meanwhile, Entergy converted Greene’s leave status from unpaid to paid and reimbursed him for a portion of his lost wages and vacation time.

No. 24-60603

Greene continued his efforts to regain “unescorted access” status. In January 2022, he submitted another urine sample, which tested positive for marijuana metabolites. Dr. Monfee ordered THCV testing, and the lab reported that “[t]he presence of THCV metabolite in [Greene’s] urine indicates prior ingestion of marijuana (or a related product) and cannot be the result of the sole use of Marinol.” Dr. Monfee discussed the results with Greene, who denied using anything other than Marinol. Greene produced a renewed prescription for Marinol, but it was dated just one day before he submitted the positive sample. Dr. Monfee “concluded that the January 17 prescription for Marinol could have had no impact on Greene’s January 18 specimen, reasoning that . . . Greene had not filled it prior to giving the urine specimen.” Greene asserted that he had “stockpiled” the Marinol, but Dr. Monfee rejected that explanation and labeled the January drug test a second FFD violation.

In February 2022, Entergy notified Greene that his unescorted access authorization was permanently revoked due to a second FFD violation and placed him on unpaid leave. Entergy also updated Greene’s PADS record to reflect the revocation.

Greene appealed Dr. Monfee’s determination. During the appeal process, Greene disclosed that he had used hemp-derived yet “legal” THCV products that he purchased while employed at Entergy. Both MROs stated that Greene had never mentioned using these products when questioned about his test results. Greene’s appeal failed, and Entergy terminated his employment in April 2022.

Free access — add to your briefcase to read the full text and ask questions with AI

Greene v. Entergy Operations, (5th Cir. 2025).

Greene v. Entergy Operations (Greene v. Entergy Operations) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Little v. Liquid Air Corp.
37 F.3d 1069 (Fifth Circuit, 1994)
Krieser Ex Rel. Krieser v. Hobbs
166 F.3d 736 (Fifth Circuit, 1999)
Gales v. CBS Broadcasting, Inc.
124 F. App'x 275 (Fifth Circuit, 2005)
Caterpillar Inc. v. Lewis
519 U.S. 61 (Supreme Court, 1996)
Gerald Kyle v. Circus Circus Mississippi, Inc
430 F. App'x 247 (Fifth Circuit, 2011)
Michael Gerhart v. Exelon Corp
461 F. App'x 143 (Third Circuit, 2012)
Anson McFaul v. Daniel Valenzuela
684 F.3d 564 (Fifth Circuit, 2012)
Cheryl Likens v. Hartford Life & Accident Ins
688 F.3d 197 (Fifth Circuit, 2012)
Pegues v. Emerson Electric Co.
913 F. Supp. 976 (N.D. Mississippi, 1996)
Perry v. Sears, Roebuck & Co.
508 So. 2d 1086 (Mississippi Supreme Court, 1987)
Leaf River Forest Products, Inc. v. Ferguson
662 So. 2d 648 (Mississippi Supreme Court, 1995)
McArn v. Allied Bruce-Terminix Co., Inc.
626 So. 2d 603 (Mississippi Supreme Court, 1993)
Kelly v. Mississippi Valley Gas Co.
397 So. 2d 874 (Mississippi Supreme Court, 1981)
Jenkins v. City of Grenada, Miss.
813 F. Supp. 443 (N.D. Mississippi, 1993)
Speed v. Scott
787 So. 2d 626 (Mississippi Supreme Court, 2001)
Senseney v. Mississippi Power Co.
914 So. 2d 1225 (Court of Appeals of Mississippi, 2005)
Gales v. CBS Broadcasting, Inc.
269 F. Supp. 2d 772 (S.D. Mississippi, 2003)
Vantage Drilling Company v. Hsin-Chi Su
741 F.3d 535 (Fifth Circuit, 2014)
Maurice Goudeau v. National Oilwell Varco, L.P.
793 F.3d 470 (Fifth Circuit, 2015)